Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 297

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS

Open access
Malcovati, Luca, Stevenson, Kristen, Papaemmanuil, Elli, Neuberg, Donna, Bejar, Rafael, Boultwood, Jacqueline, Bowen, David T., Campbell, Peter J., Ebert, Benjamin L., Fenaux, Pierre, Haferlach, Torsten, Heuser, Michael, Jansen, Joop H., Komrokji, Rami S., Maciejewski, Jaroslaw P., Walter, Matthew J., Fontenay, Michaela, Garcia-Manero, Guillermo, Graubert, Timothy A., Karsan, Aly, Meggendorfer, Manja, Pellagatti, Andrea, Sallman, David A., Savona, Michael R., Sekeres, Mikkael A., Steensma, David P., Tauro, Sudhir, Thol, Felicitas, Vyas, Paresh, Van de Loosdrecht, Arjan A., Haase, Detlef, Tüchler, Heinz, Greenberg, Peter L., Ogawa, Seishi, Hellstrom-Lindberg, Eva, Cazzola, Mario·2020·Blood

Abstract

The 2016 revision of the World Health Organization classification of tumors of hematopoietic and lymphoid tissues is characterized by a closer integration of morphology and molecular genetics. Notwithstanding, the myelodysplastic syndrome (MDS) with isolated del(5q) remains so far the only MDS subtype defined by a genetic abnormality. Approximately half of MDS patients carry somatic mutations in spliceosome genes, with SF3B1 being the most commonly mutated one. SF3B1 mutation identifies a condition characterized by ring sideroblasts (RS), ineffective erythropoiesis, and indolent clinical course. A large body of evidence supports recognition of SF3B1-mutant MDS as a distinct nosologic entity. To further validate this notion, we interrogated the data set of the International Working Group for the Prognosis of MDS (IWG-PM). Based on the findings of our analyses, we propose the following diagnostic criteria for SF3B1-mutant MDS: (1) cytopenia as defined by standard hematologic values, (2) somatic SF3B1 mutation, (3) morphologic dysplasia (with or without RS), and (4) bone marrow blasts <5% and peripheral blood blasts <1%. Selected concomitant genetic lesions represent exclusion criteria for the proposed entity. In patients with clonal cytopenia of undetermined significance, SF3B1 mutation is almost invariably associated with subsequent development of overt MDS with RS, suggesting that this genetic lesion might provide presumptive evidence of MDS in the setting of persistent unexplained cytopenia. Diagnosis of SF3B1-mutant MDS has considerable clinical implications in terms of risk stratification and therapeutic decision making. In fact, this condition has a relatively good prognosis and may respond to luspatercept with abolishment of the transfusion requirement.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2020004850

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Cited by

See all 297

Metadata

Authors
Malcovati, L., Stevenson, K., Papaemmanuil, E., Neuberg, D., Bejar, R., Boultwood, J., Bowen, D. T., Campbell, P. J., Ebert, B. L., Fenaux, P., Haferlach, T., Heuser, M., Jansen, J. H., Komrokji, R. S., Maciejewski, J. P., Walter, M. J., Fontenay, M., Garcia-Manero, G., Graubert, T. A., Karsan, A., Meggendorfer, M., Pellagatti, A., Sallman, D. A., Savona, M. R., Sekeres, M. A., Steensma, D. P., Tauro, S., Thol, F., Vyas, P., Van de Loosdrecht, A. A., Haase, D., Tüchler, H., Greenberg, P. L., Ogawa, S., Hellstrom-Lindberg, E., & Cazzola, M.
Venue
Blood
Published
2020-07-09
Volume
136
Issue
2
Pages
157-170
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W3017704884
Cited by
297
References
53
FWCI
24.44
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. https://app.cochat.ai/papers/10.1182/blood.2020004850
The paper
Malcovati, L., Stevenson, K., Papaemmanuil, E., Neuberg, D., Bejar, R., Boultwood, J., Bowen, D. T., Campbell, P. J., Ebert, B. L., Fenaux, P., Haferlach, T., Heuser, M., Jansen, J. H., Komrokji, R. S., Maciejewski, J. P., Walter, M. J., Fontenay, M., Garcia-Manero, G., Graubert, T. A., . . . Cazzola, M. (2020). SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood. https://doi.org/10.1182/blood.2020004850

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.